Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.

Patel P, Bush T, Overton T, Baker J, Hammer J, Kojic E, Conley L, Henry K, Brooks JT; SUN Study Investigators..

Antivir Ther. 2012;17(4):755-61. doi: 10.3851/IMP2020.

PMID:
22301072
2.

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.

Martínez E, Larrousse M, Podzamczer D, Pérez I, Gutiérrez F, Loncá M, Barragán P, Deulofeu R, Casamitjana R, Mallolas J, Pich J, Gatell JM; BICOMBO Study Team..

AIDS. 2010 Jan 28;24(3):F1-9. doi: 10.1097/QAD.0b013e32833562c5.

PMID:
20009917
3.

Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.

Padilla S, Masiá M, García N, Jarrin I, Tormo C, Gutiérrez F.

BMC Infect Dis. 2011 Feb 4;11:40. doi: 10.1186/1471-2334-11-40.

4.

Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.

Rasmussen TA, Tolstrup M, Melchjorsen J, Frederiksen CA, Nielsen US, Langdahl BL, Østergaard L, Laursen AL.

BMC Infect Dis. 2011 Oct 4;11:267. doi: 10.1186/1471-2334-11-267.

5.

Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.

Wohl DA, Arnoczy G, Fichtenbaum CJ, Campbell T, Taiwo B, Hicks C, McComsey GA, Koletar S, Sax P, Tebas P, Ha B, Massengale K, Walsh K, Stein JH.

Antivir Ther. 2014;19(2):141-7. doi: 10.3851/IMP2681.

6.

Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.

Saumoy M, Ordoñez-Llanos J, Martínez E, Barragán P, Ribera E, Bonet R, Knobel H, Negredo E, Loncá M, Curran A, Gatell JM, Podzamczer D; Bicombo-met Substudy Team..

Antivir Ther. 2011;16(4):459-68. doi: 10.3851/IMP1785.

PMID:
21685533
7.

Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy.

Kristoffersen US, Kofoed K, Kronborg G, Benfield T, Kjaer A, Lebech AM.

HIV Med. 2009 Nov;10(10):627-33.

PMID:
19891054
8.

Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.

Francisci D, Falcinelli E, Belfiori B, Petito E, Fierro T, Baldelli F, Gresele P.

AIDS Patient Care STDS. 2011 Oct;25(10):567-9. doi: 10.1089/apc.2011.0184. No abstract available.

PMID:
21851265
9.

Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.

Kim C, Gupta SK, Green L, Taylor BM, Deuter-Reinhard M, Desta Z, Clauss M.

Antivir Ther. 2011;16(8):1335-9. doi: 10.3851/IMP1891.

PMID:
22155915
10.

A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.

Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C, Reilly G; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK..

AIDS. 2006 Oct 24;20(16):2043-50.

PMID:
17053350
11.

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, Ribera E, Knobel H, Roca V, Gutiérrez F, Blanco JL, Mallolas J, Llibre JM, Clotet B, Dalmau D, Segura F, Arribas JR, Cosín J, Barrufet P, Casas E, Ferrer E, Curran A, González A, Pich J, Cruceta A, Arnaiz JA, Miró JM, Gatell JM; BICOMBO Study Team..

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):290-7. doi: 10.1097/QAI.0b013e3181aa12d5.

PMID:
19398921
12.

Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.

Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P.

Clin Infect Dis. 2011 Jul 1;53(1):84-91. doi: 10.1093/cid/cir269.

PMID:
21653308
13.

Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial.

Martin A, Amin J, Cooper DA, Carr A, Kelleher AD, Bloch M, Baker D, Woolley I, Emery S; STEAL study group..

AIDS. 2010 Nov 13;24(17):2657-63. doi: 10.1097/QAD.0b013e32833f147f.

PMID:
20827168
14.
15.

Anti-HIV agents. Trying times for tenofovir and abacavir.

[No authors listed]

TreatmentUpdate. 2003 Oct;15(6):2-3. No abstract available.

PMID:
17216860
16.

Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.

De Luca A, de Gaetano Donati K, Cozzi-Lepri A, Colafigli M, De Curtis A, Capobianchi MR, Antinori A, Giacometti A, Magnani G, Vullo V, Cauda R, Iacoviello L, d'Arminio Monforte A; ICoNA Foundation Study Group..

J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):e98-101. doi: 10.1097/QAI.0b013e318259875b. No abstract available.

PMID:
22728753
17.

Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.

Maggi P, Montinaro V, Bellacosa C, Pietanza S, Volpe A, Graziano G, Strippoli GF, Angarano G.

AIDS Patient Care STDS. 2012 Jan;26(1):5-11. doi: 10.1089/apc.2011.0185.

PMID:
22136504
18.

Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.

Tan DH, Chan K, Raboud J, Cooper C, Montaner JS, Walmsley S, Hogg RS, Klein MB, Machouf N, Rourke SB, Tsoukas C, Loutfy MR; CANOC Collaboration..

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):38-46. doi: 10.1097/QAI.0b013e3182282cfc.

PMID:
21709570
19.

Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.

Calza L, Magistrelli E, Danese I, Colangeli V, Borderi M, Bon I, Re MC, Mancini R, Conti M, Motta R, Viale P.

Curr HIV Res. 2016;14(1):61-70.

PMID:
26531764
20.

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.

Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, Liao Q, Ross L, Johnson J, Shaefer MS; ESS30009 Study..

J Infect Dis. 2005 Dec 1;192(11):1921-30.

PMID:
16267763

Supplemental Content

Support Center